Development of investigational insomnia drug daridorexant progresses following positive phase III trial data

In study (n=930) examining 25mg and 50mg doses of this dual orexin receptor antagonist, participants were able to fall asleep and stay asleep, and saw an improvement in their daytime performance. Company is hoping to launch drug worldwide by end of 2021 or start of 2022.


Biospace Inc.